Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02OJC
|
||||
| Former ID |
DCL000663
|
||||
| Drug Name |
Xaliproden
|
||||
| Synonyms |
Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease; Peripheral sensory neuropathies; Lateral sclerosis [ICD9: 331.0, 356.0, 356.8; ICD10:G30, G64, G90.0, G12.2] | Discontinued in Phase 3 | [1] | ||
| Company |
Sanofi-Aventis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H22F3N
|
||||
| Canonical SMILES |
C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
|
||||
| InChI |
1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2
|
||||
| InChIKey |
WJJYZXPHLSLMGE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 428863-50-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
N07XX03
|
||||
| SuperDrug CAS ID |
cas=135354028
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001601) | ||||
| REF 2 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.